Novo Nordisk (NVO) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The study “A Study Investigating the Effect of Cagrilintide on Energy Intake and Appetite in People With Overweight or Obesity” aims to see how Novo Nordisk’s drug changes how much people eat and how hungry they feel. It focuses on adults with overweight or obesity, and could help guide the next wave of weight loss treatments if results are positive.
The main treatment is cagrilintide, an injectable drug given once a week under the skin. It is designed to lower appetite and help people eat less, and it is tested against a look‑alike placebo that has no active ingredient.
The study is interventional and uses random assignment so each participant has a fair chance to get cagrilintide or placebo. It is run as a parallel‑group trial with both participants and study staff blinded, and the main goal is to test treatment effects on appetite and energy intake, not just to observe.
The trial is listed as recruiting, with first submission on 2026‑04‑23, signalling a very early‑stage program. The latest update on 2026‑05‑13 shows the record is active and maintained, and investors should expect a multi‑year path before final completion and public readouts.
For NVO, this update underlines its push to deepen its obesity pipeline beyond current GLP‑1 drugs, which can support long‑term growth narratives and valuation multiples. Competitors like Eli Lilly and others in obesity care will watch closely, as any signal that cagrilintide enhances or complements existing therapies could raise expectations for future revenue and further fuel sector enthusiasm.
The study is ongoing with details and future updates available on the ClinicalTrials portal.
To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.